Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Standard Biotools (LAB) Long-Term Debt Repayments (2021 - 2024)

Standard Biotools has reported Long-Term Debt Repayments over the past 6 years, most recently at $55.0 million for Q4 2024.

  • Quarterly Long-Term Debt Repayments rose 4300.0% to $55.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $55.0 million through Sep 2025, up 482.5% year-over-year, with the annual reading at $63.2 million for FY2024, 2933.7% up from the prior year.
  • Long-Term Debt Repayments was $55.0 million for Q4 2024 at Standard Biotools, up from $8.2 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $55.0 million in Q4 2024 and troughed at $501000.0 in Q1 2021.
  • The 4-year median for Long-Term Debt Repayments is $1.0 million (2023), against an average of $9.2 million.
  • Year-over-year, Long-Term Debt Repayments skyrocketed 1264.87% in 2022 and then surged 4300.0% in 2024.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $501000.0 in 2021, then skyrocketed by 1264.87% to $6.8 million in 2022, then tumbled by 81.72% to $1.2 million in 2023, then surged by 4300.0% to $55.0 million in 2024.
  • Per Business Quant, the three most recent readings for LAB's Long-Term Debt Repayments are $55.0 million (Q4 2024), $8.2 million (Q1 2024), and $1.2 million (Q4 2023).